PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

September 27, 2012

Primary Completion Date

September 12, 2017

Study Completion Date

October 25, 2018

Conditions
Advanced MelanomaMetastatic Melanoma
Interventions
BIOLOGICAL

Nivolumab

DRUG

Ipilimumab

Trial Locations (14)

10065

Memorial Sloan-Kettering Cancer Center, New York

21093

Sidney kimmel comprehensive cancer center at johns hopkins, Lutherville

22908

University Of Virginia, Charlottesville

31192

Local Institution - 0008, Pamplona

37232

Vanderbilt-Ingram Cancer Ctr, Nashville

77030

The University Of Texas MD Anderson Cancer Center, Houston

90095

Ucla, Los Angeles

97213

Providence Portland Medical Center, Portland

98109

University of Washington - Seattle Cancer Care Alliance, Seattle

60637-1443

University Of Chicago, Chicago

02215

Beth Israel Deaconess Medical Center (BIDMC), Boston

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

1066 CX

Local Institution - 0016, Amsterdam

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01621490 - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | Biotech Hunter | Biotech Hunter